JPRN-UMIN000011914招募中未知
A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly HLA-sensitized Transplant Patients. - A Phased Desensitization Protocol for DSA-positive Patients.
Transplantation Surgery, Hiroshima University Hospital0 个研究点目标入组 30 人开始时间: 2013年9月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with current or recent severe systemic infections requiring treatment (systemic antibiotics, antivirals, or antifungals). Serious diarrhea, active ulcer or uncontrolled diabetes likely to interfere with participation in this clinical study. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Known history of allergy to rituximab or bortezomib. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Female subject is pregnant or breast-feeding. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
研究者
相似试验
招募中
不适用
Desensitization with rituximab for preformed anti-donor antibody and antibody-mediated rejection in kidney transplantation.end stage renal diseaseJPRN-UMIN000032113Hyogo College of Medicine90
招募中
不适用
Clinical trial of Rituximab for desensitization or antibody mediated rejection therapy in anti-donor HLA antibody positive patientsChronic renal dysfunction or post kidney transplant recipientsJPRN-jRCTs031180323Saito Kazuhide20
进行中（未招募）
不适用
Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma - IILFLE09EUCTR2009-012337-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
进行中（未招募）
不适用
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IFEUCTR2005-004761-42-ESFundacion Leucemia y Linfoma